help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kraaij, R.
Right arrow Articles by Themmen, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraaij, R.
Right arrow Articles by Themmen, A. P.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 3168-3172, Copyright © 1995 by Endocrine Society


ARTICLES

A missense mutation in the second transmembrane segment of the luteinizing hormone receptor causes familial male-limited precocious puberty

R Kraaij, M Post, H Kremer, E Milgrom, W Epping, HG Brunner, JA Grootegoed and AP Themmen
Department of Endocrinology and Reproduction, Erasmus University Rotterdam, The Netherlands.

Patients with familial male-limited precocious puberty present with early onset of puberty. Several missense mutations in the LH receptor gene that cause amino acid substitutions in the sixth transmembrane segment of the receptor protein have been shown to be a cause of the disorder. We have identified a novel LH receptor gene mutation in a patient with familial male-limited precocious puberty that results in a threonine for methionine substitution at position 398 in the second transmembrane segment of the receptor protein. In vitro expression in human embryonic kidney 293 cells of this LH receptor mutant and two previously described LH receptor mutants showed that cAMP production in the absence of hormone was elevated up to 25-fold compared to the basal level of the wild-type receptor. The ED50 values of hormone-induced cAMP production were within the same range for wild-type and mutant receptors, but maximal hormone-induced cAMP production was relatively low for mutant receptors. We also produced receptors containing amino acid substitutions in both the second and sixth transmembrane segments. For these double mutants, basal receptor activities were similar to the basal activities observed in single mutants, whereas hormone-induced receptor activation was almost completely abolished.


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Bruysters, M. Verhoef-Post, and A. P. N. Themmen
Asp330 and Tyr331 in the C-terminal Cysteine-rich Region of the Luteinizing Hormone Receptor Are Key Residues in Hormone-induced Receptor Activation
J. Biol. Chem., September 19, 2008; 283(38): 25821 - 25828.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Bruysters, S. Christin-Maitre, M. Verhoef-Post, C. Sultan, J. Auger, I. Faugeron, L. Larue, S. Lumbroso, A.P.N. Themmen, and P. Bouchard
A new LH receptor splice mutation responsible for male hypogonadism with subnormal sperm production in the propositus, and infertility with regular cycles in an affected sister
Hum. Reprod., August 1, 2008; 23(8): 1917 - 1923.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Piersma, E. M. J. J. Berns, M. Verhoef-Post, A. G. Uitterlinden, I. Braakman, H. A. P. Pols, and A. P. N. Themmen
A Common Polymorphism Renders the Luteinizing Hormone Receptor Protein More Active by Improving Signal Peptide Function and Predicts Adverse Outcome in Breast Cancer Patients
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1470 - 1476.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Richter-Unruh, M. Verhoef-Post, S. Malak, J. Homoki, B. P. Hauffa, and A. P. N. Themmen
Leydig Cell Hypoplasia: Absent Luteinizing Hormone Receptor Cell Surface Expression Caused by a Novel Homozygous Mutation in the Extracellular Domain
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5161 - 5167.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
F. Fanelli, M. Verhoef-Post, M. Timmerman, A. Zeilemaker, J. W. M. Martens, and A. P. N. Themmen
Insight into Mutation-Induced Activation of the Luteinizing Hormone Receptor: Molecular Simulations Predict the Functional Behavior of Engineered Mutants at M398
Mol. Endocrinol., June 1, 2004; 18(6): 1499 - 1508.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Angelova, F. Fanelli, and D. Puett
A Model for Constitutive Lutropin Receptor Activation Based on Molecular Simulation and Engineered Mutations in Transmembrane Helices 6 and 7
J. Biol. Chem., August 23, 2002; 277(35): 32202 - 32213.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Ascoli, F. Fanelli, and D. L. Segaloff
The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective
Endocr. Rev., April 1, 2002; 23(2): 141 - 174.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Richter-Unruh, H. T. Wessels, U. Menken, M. Bergmann, K. Schmittmann-Ohters, J. Schaper, S. Tappeser, and B. P. Hauffa
Male LH-Independent Sexual Precocity in a 3.5-Year-Old Boy Caused by a Somatic Activating Mutation of the LH Receptor in a Leydig Cell Tumor
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1052 - 1056.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. C. Latronico, H. Shinozaki, G. Guerra Jr., M. A. A. Pereira, S. H. V. Lemos Marini, M. T. M. Baptista, I. J. P. Arnhold, F. Fanelli, B. B. Mendonca, and D. L. Segaloff
Gonadotropin-Independent Precocious Puberty Due to Luteinizing Hormone Receptor Mutations in Brazilian Boys: A Novel Constitutively Activating Mutation in the First Transmembrane Helix
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4799 - 4805.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
A. P. N. Themmen and I. T. Huhtaniemi
Mutations of Gonadotropins and Gonadotropin Receptors: Elucidating the Physiology and Pathophysiology of Pituitary-Gonadal Function
Endocr. Rev., October 1, 2000; 21(5): 551 - 583.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Kremer, J. W. M. Martens, M. van Reen, M. Verhoef-Post, J. M. Wit, B. J. Otten, S. L. S. Drop, H. A. Delemarre-van de Waal, M. Pombo-Arias, F. De Luca, et al.
A Limited Repertoire of Mutations of the Luteinizing Hormone (LH) Receptor Gene in Familial and Sporadic Patients with Male LH-Independent Precocious Puberty
J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 1136 - 1140.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
A. N. Abell, D. J. McCormick, and D. L. Segaloff
Certain Activating Mutations within Helix 6 of the Human Luteinizing Hormone Receptor May Be Explained by Alterations That Allow Transmembrane Regions to Activate Gs
Mol. Endocrinol., December 1, 1998; 12(12): 1857 - 1869.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
A. C. Latronico, A. N. Abell, I. J. P. Arnhold, X. Liu, T. S. S. Lins, V. N. Brito, A. E. Billerbeck, D. L. Segaloff, and B. B. Mendonca
A Unique Constitutively Activating Mutation in Third Transmembrane Helix of Luteinizing Hormone Receptor Causes Sporadic Male Gonadotropin-Independent Precocious Puberty
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2435 - 2440.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
J. W. M. Martens, M. Verhoef-Post, N. Abelin, M. Ezabella, S. P. A. Toledo, H. G. Brunner, and A. P. N. Themmen
A Homozygous Mutation in the Luteinizing Hormone Receptor Causes Partial Leydig Cell Hypoplasia: Correlation between Receptor Activity and Phenotype
Mol. Endocrinol., June 1, 1998; 12(6): 775 - 784.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
S. Kosugi, T. Mori, and A. Shenker
An Anionic Residue at Position 564 Is Important for Maintaining the Inactive Conformation of the Human Lutropin/Choriogonadotropin Receptor
Mol. Pharmacol., May 1, 1998; 53(5): 894 - 901.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Yano, L. D. Kohn, M. Saji, A. Okuno, and G. B. Cutler Jr.
Phe576 Plays an Important Role in the Secondary Structure and Intracellular Signaling of the Human Luteinizing Hormone/Chorionic Gonadotropin Receptor
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2586 - 2591.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. P. Cohen, C. N. Thaw, A. Varma, M. C. Gershengorn, and D. R. Nussenzveig
Human Calcitonin Receptors Exhibit Agonist-Independent (Constitutive) Signaling Activity
Endocrinology, April 1, 1997; 138(4): 1400 - 1405.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kosugi, T. Mori, and A. Shenker
The Role of Asp578 in Maintaining the Inactive Conformation of the Human Lutropin/Choriogonadotropin Receptor
J. Biol. Chem., December 13, 1996; 271(50): 31813 - 31817.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Kudo, Y. Osuga, B. K. Kobilka, and A. J.W. Hsueh
Transmembrane Regions V and VI of the Human Luteinizing Hormone Receptor Are Required for Constitutive Activation by a Mutation in the Third Intracellular Loop
J. Biol. Chem., September 13, 1996; 271(37): 22470 - 22478.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society